Related Experiment Videos
Adjuvant chemo-radiotherapy in ampullary cancers
S S Sikora1, P Balachandran, K Dimri
1Department of Surgical Gastroenterology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow 226014, India. sadiqss@sgpgi.ac.in
Summary
Adjuvant chemo-radiotherapy did not improve survival or reduce recurrence in ampullary cancer patients after surgery. This study found no significant benefit for patients receiving this treatment post-pancreaticoduodenectomy.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Ampullary cancers often recur locally after surgery, with up to 45% of patients experiencing loco-regional recurrence.
- The role of adjuvant chemo-radiotherapy in improving outcomes for ampullary cancer remains unclear.
Purpose of the Study:
- To evaluate the impact of adjuvant chemo-radiotherapy on survival and loco-regional control in patients with ampullary cancer following pancreaticoduodenectomy.
Main Methods:
- A retrospective analysis of 104 patients who underwent pancreaticoduodenectomy for ampullary cancer between 1989 and 2000.
- Comparison of long-term outcomes between 49 patients who received adjuvant chemo-radiotherapy (50.4 Gy with 5-Fluorouracil) and 55 patients who did not.
Main Results:
- No significant difference in median survival (34.6 vs 24.5 months) or 5-year survival rates (38% vs 28%) was observed between the adjuvant chemo-radiotherapy group and the control group.
- Adjuvant chemo-radiotherapy did not impact survival in high-risk patients or influence loco-regional recurrence rates.
Conclusions:
- Adjuvant chemo-radiotherapy following pancreaticoduodenectomy does not enhance long-term survival for ampullary cancer patients.
- This treatment modality did not demonstrate a reduction in recurrence rates for this patient cohort.